Sugi Predict

Sugi Predict / Compounds / SCHEMBL2587336

SCHEMBL2587336

SCHEMBL2587336

CC(C)(C)C(=O)Nc1cc(Cl)nc(Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR2 O95136 2/20 0.62
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ GAA P10253 1/20 0.50
▸ BCHE P06276 1/20 0.46
▸ ACHE P22303 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ MAPT P10636 3/20 0.45
▸ HTT P42858 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ ADORA1 P30542 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26624177 0.87 S1PR2 (0.60) S1PR2L3MBTL1GAABCHEACHE
SCHEMBL26624095 0.85 S1PR2 (0.58) S1PR2L3MBTL1BCHEACHE
SCHEMBL23060370 0.82 S1PR2 (0.64) S1PR2L3MBTL1GAABCHEACHE
SCHEMBL26624196 0.82 S1PR2 (0.55) S1PR2BCHEACHE
SCHEMBL26624096 0.82 S1PR2 (0.55) S1PR2L3MBTL1BCHEACHE
SCHEMBL23441 0.81 L3MBTL1 (0.73) L3MBTL1GAANPSR1MAPTHTT
SCHEMBL23060376 0.81 S1PR2 (0.62) S1PR2L3MBTL1GAABCHEACHE
SCHEMBL3786382 0.80 L3MBTL1 (0.59) L3MBTL1GAANPSR1MAPTHTT
SCHEMBL14254938 0.80 L3MBTL1 (0.59) L3MBTL1GAANPSR1MAPTHTT
SCHEMBL26624149 0.80 S1PR2 (0.51) S1PR2BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12358931-B2 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor THERAVANCE BIOPHARMA R&D IP, LLC (US) 2025-07-15 — — US disclosed
US-20240132520-A1 NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2024-04-25 — — US disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF InventisBio Co., Ltd. (CN) 2023-11-09 — — US disclosed
US-11780852-B2 Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile THERAVANCE BIOPHARMA R&D IP, LLC (US) 2023-10-10 — — US disclosed
CN-111362975-B Naphthyridine compounds as JAK kinase inhibitors 施万生物制药研发IP有限责任公司 2022-04-05 — — CN disclosed
US-20210179637-A1 NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-06-17 — — US disclosed
US-10947254-B2 Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile THERAVANCE BIOPHARMA R&D IP, LLC (US) 2021-03-16 — — US disclosed
CN-111362975-A Naphthyridine compounds as JAK kinase inhibitors 施万生物制药研发IP有限责任公司 2020-07-03 — — CN disclosed
CN-107667108-B Naphthyridine compounds as JAK kinase inhibitors 施万生物制药研发IP有限责任公司 2020-05-12 — — CN disclosed
EP-2563789-B1 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS GLAXO GROUP LTD (GB) 2015-05-20 — — EP disclosed
US-8633319-B2 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors GLAXO GROUP LIMITED (GB) 2014-01-21 — — US disclosed
US-8633319-B2 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors GLAXO GROUP LIMITED (GB) 2014-01-21 — — US disclosed
US-8633319-B2 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors GLAXO GROUP LIMITED (GB) 2014-01-21 — — US disclosed
EP-2563789-A1 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS Glaxo Group Limited (GB) 2013-03-06 — — EP disclosed
US-20130040984-A1 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2013-02-14 — — US disclosed
US-20130040984-A1 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2013-02-14 — — US disclosed
US-20130040984-A1 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2013-02-14 — — US disclosed
WO-2011134971-A1 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2011-11-03 — — WO disclosed
WO-2011134971-A1 7-(1H-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2011-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358931-B2 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor JAK1, JAK3, JAK2 S1PR2 2144/4885L3MBTL1 2360/4885GAA 2950/4885
US-20130040984-A1 7-(lH-PYRAZOL-4-YL)-1,6-NAPHTHYRIDINE COMPOUNDS AS SYK INHIBITORS SYK, BTK, LYN S1PR2 957/4885L3MBTL1 1389/4885GAA 952/4885
US-11780852-B2 Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile ALPI, TPMT, SLC10A2 S1PR2 162/4885L3MBTL1 4762/4885GAA 429/4885
US-10947254-B2 Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile ALPI, TPMT, SI S1PR2 537/4885L3MBTL1 4597/4885GAA 2390/4885
US-20210179637-A1 NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS JAK1, JAK2, JAK3 S1PR2 1958/4885L3MBTL1 4819/4885GAA 1536/4885
US-20230357233-A1 HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF KRAS, NRAS, HRAS S1PR2 1135/4885L3MBTL1 4619/4885GAA 3036/4885
US-20240132520-A1 NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS JAK1, JAK2, JAK3 S1PR2 1958/4885L3MBTL1 4819/4885GAA 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.